We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TVRD:NASDAQTvardi Therapeutics, Inc. Analysis

Data as of 2026-09-01 - not real-time

$1.79

Latest Price

9/10Risk

Risk Level: High

Executive Summary

The moving-average structure behind Tvardi Therapeutics, Inc. is bearish at $1.79, with short-term averages lagging the long-term ones. Over a rolling month the price has lost 37.4%. With RSI at 38.9 the momentum picture is approaching oversold, alongside a bullish MACD signal. Recent trading has carved out support near $1.70 and resistance around $2.04.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 374.9% above today's level.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 59.9%, a beta of 0.44 and a maximum drawdown of 96.5%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
All three time horizons resolve to hold, carrying 1/10 conviction.

Top Market Events

SUGAR LAND, Texas AP — SUGAR LAND, Texas AP — Tvardi Therapeutics, Inc.Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design,...Tvardi Therapeutics To Host KOL Webinar On The Clinical Potential Of TTI-109 In Ulcerative Colitis UC And The Evolving...

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 2/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • Trading below the 200-day average of 3.35
  • MACD momentum is positive

Medium Term

1–3 years
Neutral
Model confidence: 1/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • Trading below the 200-day average of 3.35
  • Analyst targets imply +374.9% versus the current price

Long Term

> 3 years
Neutral
Model confidence: 1/10

Key Factors

  • Analyst targets imply +374.9% versus the current price
  • Negative return on equity of -126.2%
  • Negative free cash flow

Key Metrics & Analysis

Financial Health

P/E Ratio-0.8
ROE-126.19%
ROA-55.51%
Debt/Equity1.73
P/B Ratio1.2
Op. Cash Flow$-25029000
Free Cash Flow$-16258125
Industry P/E30.6

Technical Analysis

TrendBearish
RSI38.9
Support$1.70
Resistance$2.04
MA 20$1.83
MA 50$2.30
MA 200$3.35
MACDBullish
VolumeDecreasing
Fear & Greed Index92.95

Valuation

Target Price$8.50
Upside/Downside374.86%
GradeFair
TypeBlend

Risk Assessment

Beta0.44
Volatility59.92%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.